chufangao/CTO huggingface dataset:
Clinical trial NCT03348163: (mo)BETTA Trial in Transwomen for Optimization of ART
Official title: Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial
Acronym: (mo)BETTA
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of ability to recruit due to COVID-19 pandemic
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-06
Primary completion date: 2020-12-15
Completion date: 2020-12-15
Clinical trial NCT04041362: the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
Official title: A Phase II, Open-label, Controlled, Proof-of-concept Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
Sponsor: United BioPharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study will not be submitted to authority for IND application.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2020-12-31
Completion date: 2021-03-31
Plan to share individual participant data: NO
Clinical trial NCT05097651: CBD for Sleep in People With HIV
Official title: Pilot Trial of Cannabidiol (CBD) for Sleep Problems in People With HIV
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Difficulties enrolling eligible participants
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-01
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: YES
IPD sharing description: Data and biospecimens collected in the course of this study will be stored in the joint HIV Neurobehavioral Research Center (HNRP) - Center for Medicinal Cannabis Research (CMCR) Data and Biospecimen Repositories for potential future use. De-identified data and biospecimens may be made available to investigators conducting institutional review board (IRB) approved research. Interested investigators will submit a request for data and/or biospecimens. HNRP-CMCR leadership will be responsible for determining who will have access to the data and biospecimens and will ensure that a Data Use Agreement is signed by the requesting investigator. The data and biospecimens will be stored indefinitely, however, if a research participant decides they no longer want their biospecimens to be used, all efforts will be made to stop any additional studies.
IPD time frame: The data and biospecimens will become available following publication. Data and biospecimens will be stored indefinitely, however, if a research participant decides they no longer want their biospecimens to be used, all efforts will be made to stop any additional studies.
IPD access criteria: Investigators whose proposed use of the data and/or biospecimens has been approved by the HNRP-CMCR leadership. HNRP-CMCR leadership will ensure that a Data Use Agreement is signed by the requesting investigator.
Clinical trial NCT03905655: Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
Official title: Randomized Double-Blind Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B Virologically Suppressed for at Least Twelve Months on Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide or Entecavir
Sponsor: Romark Laboratories L.C. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 51.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-22
Primary completion date: 2021-03-10
Completion date: 2021-10-11
Baseline population: All subjects receiving at least one dose of study medication
Limitations and caveats: This study was a pilot study with a small number of participants.
Plan to share individual participant data: NO
Clinical trial NCT04347512: EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA
Official title: EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA
Acronym: TEACHCOVID
Sponsor: University Hospital, Strasbourg, France (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: In view of the notices concerning hydroxychloroquine issued by the regulatory authorities, we withdraw the protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-02
Primary completion date: 2020-06-02
Completion date: 2020-06-02
Plan to share individual participant data: NO
Clinical trial NCT04599972: An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
Official title: A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (the NEAR-2 Study: Near Eye-vision Acuity Restoration)
Acronym: NEAR-2
Sponsor: Orasis Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 304.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-26
Primary completion date: 2022-01-21
Completion date: 2022-01-28
Clinical trial NCT03992716: Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness
Official title: Reaching Protein Target With SmofKabiven® Extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute Critical Illness
Sponsor: Fresenius Kabi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study had to be put on hold after the outbreak of Covid-19 in the participating countries and was terminated in September 2020 since a date for re-starting was not foreseeable.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-26
Primary completion date: 2020-03-24
Completion date: 2020-03-24
Plan to share individual participant data: NO
Clinical trial NCT05295784: PK and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia
Official title: Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Data no longer support this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2024-05-08
Primary completion date: 2024-05-08
Completion date: 2024-05-08
Plan to share individual participant data: NO
Clinical trial NCT03688633: Candesartan in Peripheral Neuropathy
Official title: Pilot Study, Single-blind, Candesartan Versus Usual Care of Peripheral Neuropathy Development Induced by Vincristine (PNIV) in Patients Treated for Lymphoma B
Acronym: NEUPERSART
Sponsor: University Hospital, Limoges (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Patient Recruitment Failure
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-01
Primary completion date: 2021-05-27
Completion date: 2021-05-27
Plan to share individual participant data: NO
Clinical trial NCT03969719: A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Official title: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED DAILY FOR 16 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS ON METFORMIN
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 164.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-07-18
Primary completion date: 2021-03-02
Completion date: 2021-03-30
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03846193: FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
Official title: FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD
Sponsor: Gyroscope Therapeutics Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to the interim analysis demonstrating lack of treatment efficacy
Enrollment: 56.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-12-17
Primary completion date: 2024-06-25
Completion date: 2024-06-25
Clinical trial NCT04075513: Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Official title: A 12-week Randomized, Controlled Trial to Compare TOUJEO® and TRESIBA® in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus
Acronym: inRange
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 343.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-09
Primary completion date: 2021-09-16
Completion date: 2021-09-16
Baseline population: Analysis was performed on intent-to-treat (ITT) population which included all randomized participants (who signed the informed consent form and were allocated to a treatment group before the first investigational medicinal product \[IMP\] administration and recorded in the IRT database), irrespective of the treatment actually received and were analyzed according to the treatment group allocated by randomization.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT02309645: The Paediatric EVICEL® Neuro Study
Official title: A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL® Used for Suture-Line Sealing in Dura-Mater Closure During Paediatric Neurosurgical Cranial Procedures
Sponsor: Ethicon, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study completed the required elements (40 paediatric subjects) per regulatory requirement. The study enrolled 40/42 subjects. No safety signals were identified. No changes required to the statistical analysis as described in the protocol.
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-10-01
Primary completion date: 2021-08-17
Completion date: 2021-09-17
Baseline population: The full analysis set (FAS) consisted of all randomized participants.
Plan to share individual participant data: YES
Clinical trial NCT03893019: MB-CART20.1 Melanoma
Official title: Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma
Sponsor: Miltenyi Biomedicine GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: The risk-benefit assessment was not as expected.
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-08
Primary completion date: 2023-01-30
Completion date: 2023-01-30
Plan to share individual participant data: NO
Clinical trial NCT05359081: A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Official title: A 52-week, Open-label Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
Sponsor: Sumitomo Pharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to company business strategy
Enrollment: 68.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-16
Primary completion date: 2024-03-21
Completion date: 2024-03-28
Plan to share individual participant data: NO
Clinical trial NCT04230122: A Study of LY3478006 in Healthy Participants
Official title: A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3478006 in Healthy Subjects
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Protocol stopping criteria (safety) were met.
Enrollment: 4.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-02-17
Primary completion date: 2020-06-04
Completion date: 2020-06-04
Baseline population: All randomized participants.
Limitations and caveats: Cohort 2 through 7 were not explored as study was terminated early for safety reasons after Cohort 1.
Plan to share individual participant data: NO
Clinical trial NCT03079297: Rapid Antidepressant Effects of Leucine
Official title: A Pilot Double-Blind Randomized Placebo-Controlled Crossover Study to Investigate Rapid Antidepressant Effects of Leucine
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Covid-19
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-09
Primary completion date: 2021-10-04
Completion date: 2021-10-04
Plan to share individual participant data: NO
Clinical trial NCT03650413: An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Official title: A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated early by the Sponsor based on the interim analysis of Study GA39925 (NCT03558152) that showed low efficacy of UTTR1147A in ulcerative colitis. Development of the drug in this indication has been terminated.
Enrollment: 143.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-14
Primary completion date: 2022-07-12
Completion date: 2022-07-12
Baseline population: There was only 1 arm in this study. The protocol was written with this single group receiving treatment based upon remission status.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).~For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04639011: Duloxetine Tibial Plateau
Official title: Effects of Duloxetine on Postoperative Pain Control and Knee Rehabilitation After Open Reduction Internal Fixation of Tibial Plateau Fractures
Sponsor: Boston Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study was not conducted because funding was not obtained.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT02898077: A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
Official title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 440.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-02
Primary completion date: 2020-06-30
Completion date: 2021-04-12
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04022876: A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Official title: A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression
Sponsor: Aileron Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size
Enrollment: 35.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-03
Primary completion date: 2022-07-30
Completion date: 2022-08-30
Clinical trial NCT04574869: A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
Official title: A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, PK, & PD of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
Sponsor: ReAlta Life Sciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Low probability of enrolling patients prior to expiry of study drug.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-01-31
Primary completion date: 2022-09-30
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT02963766: A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Official title: A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
Acronym: AWARD-PEDS
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-12-29
Primary completion date: 2021-06-12
Completion date: 2022-01-12
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03369444: A Factor IX Gene Therapy Study (FIX-GT)
Official title: A Phase I/II, Open Label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno- Associated Viral Vector (FLT180a) in Patients With Haemophilia B
Acronym: FIX-GT
Sponsor: University College, London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated early due to challenges during the COVID-19 pandemic and a change in requirements of data to be submitted for marketing authorisation.
Enrollment: 10.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-12-05
Primary completion date: 2020-10-20
Completion date: 2020-10-20
Limitations and caveats: Protocol defined number of participants (n=24) was not met, the terminal dose as specified in the protocol was not identified prior to early study termination.~The primary efficacy endpoints (FIX response at the terminal dose) could therefore not be detailed established. However the FIX response data (efficacy endpoint) for the 4 patients treated at the last studied dose level 1.3×10e\^12 vg/kg, have been presented instead.
Plan to share individual participant data: NO
Clinical trial NCT03774407: Vaginal Estriol in Multiple Sclerosis
Official title: Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)
Sponsor: Texas Tech University Health Sciences Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-20
Primary completion date: 2020-11-10
Completion date: 2020-11-29
Plan to share individual participant data: NO
Clinical trial NCT02422524: Pretomanid in Adults With Hepatic Impairment
Official title: A Phase I, Single Dose, Open-Label Study Comparing the Pharmacokinetics and Safety of Pretomanid in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The TB hepatic pretomanid PK trial is closed to enrollment. There is no possibility of enrolling and completing the CSR before November 2024.
Enrollment: 14.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-12-11
Primary completion date: 2023-08-26
Completion date: 2023-11-17
Clinical trial NCT03183596: Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery
Official title: Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery (Randomized, Pilot Study)
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Principal investigator determination
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-31
Primary completion date: 2020-08-31
Completion date: 2024-01-31
Plan to share individual participant data: NO
Clinical trial NCT03199144: Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
Official title: Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Borderline Resectable Pancreatic Cancer : Phase II Study
Acronym: CKPancreas
Sponsor: Centre Francois Baclesse, Luxembourg (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: difficulties to recruit patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-20
Primary completion date: 2021-03-19
Completion date: 2021-03-19
Plan to share individual participant data: NO